You are here : Home » MS Research News » New Discoveries » Antagonist compounds

Antagonist compounds

Share |

Antagonist compounds have potential application in multiple sclerosis

Idera Logo

Idera Pharmaceuticals, Inc. announced the publication of studies on the chemistry of novel compounds that have been shown to act as antagonists for Toll-like Receptors (TLR) 7 and 9. These antagonist candidates have potential application in autoimmune and inflammatory diseases. The paper
entitled "Oligodeoxyribonucleotide-Based Antagonists for Toll-Like Receptors 7 and 9" is published in the Journal of Medicinal Chemistry (December 2008, online ahead of print) and is authored by Daqing Wang, Ph.D., Lakshmi Bhagat, Ph.D., Dong Yu, Ph.D., Fu-Gang Zhu, Ph.D., Jimmy Tang, M.S., Ekambar Kandimalla, Ph.D., and Sudhir Agrawal, D.Phil., all of Idera.

"These novel antagonist candidates have been created through our ongoing
structure-activity relationship studies of oligonucleotides, through which we
have also identified agonists of TLR7, 8 and 9," said Sudhir Agrawal, D.Phil., Chief Executive Officer and Chief Scientific Officer. "We have evaluated selected antagonist candidates in preclinical models of lupus, rheumatoid arthritis, multiple sclerosis, psoriasis, and colitis, and studies continue in additional preclinical models of autoimmune and inflammatory diseases."

"Based on encouraging results in preclinical models, we are conducting
preclinical development studies with our lead TLR antagonist drug candidate, IMO-3100, for an intended Investigational New Drug application," said Tim Sullivan, Ph.D., Vice President of Development Programs. "Members of our Autoimmune Disease Scientific Advisory Board are assisting us in the clinical development strategy for IMO-3100 and other antagonist candidates in autoimmune and inflammatory diseases."

About IMO-3100

IMO-3100 is an antagonist drug candidate currently undergoing preclinical
development studies for an intended Investigational New Drug application.
Idera`s antagonists of Toll-like Receptors (TLR) are based on synthetic DNA and have been created through extensive structure-activity relationship studies.

IMO-3100 has been shown in preclinical assays to suppress immune responses mediated through TLR7 and TLR9. IMO-3100 has been studied in preclinical models of lupus, rheumatoid arthritis, multiple sclerosis, psoriasis, and colitis.

Evaluation of our TLR antagonists in additional preclinical models of autoimmune and inflammatory diseases is in progress.

Source: Idera Pharmaceuticals, Inc.(05/01/09)

Related Items

Abnormal Liver Tests and MS

AlphaB-crystallin

Aluminium and Multiple Sclerosis

Antibodies, B Cells,T-Cell Activation, Immune Response

Apolipoprotein D

Bacteria & MS

Biomarkers and MicroRNA

Blood tests

Bone Marrow Cells and MS Treatment

Bowmann-Birk Inhibitor Concentrate (BBIC)

Brain Atrophy, Lesion Loads, White and Grey Matter

Brain Inflammation

Brain Iron Deposits

Calcium Binding Proteins

Cerebro-Spinal Fluid & Spinal Cord

Chronic Cerebrospinal Venous Insufficiency (CCSVI)

CRMP-2

CXCL1, 7, 12

Cytokines & Chemokines

Dendritic Cells

Estrogen Receptors

Fibrinogen, Mac-1 and Microglia

HDL

HERV-Fc1

Histamine and MS

Hormones And MS Research

Immunoglobulins

Infections and Multiple Sclerosis Relapses

Interleukin-1beta

JAK-STAT inhibitors

Kallikrein 6

Lipid Hypothesis

Medical Imaging

Mycoplasmas And Bacteria

N-acetylglucosamine (GlcNAc) & Glucosamine

Natural Interferon Beta

Natural Killer Cells

Nerve and Brain Cell Research

Neurosteroids

Olig 1 Gene Discovery

Oligodendrocytes and Astrocytes

Pesticides and Multiple Sclerosis

PKC-theta

Plasma Exchange

Potential Viral Causes of MS

Proteomics

Recombinant Human Erythropoietin

Regeneration Research

RNA and RNAi

Synthetic Small Molecules

Technology

Tetanus Vaccine and Possible MS Protection

Tetramers

The Blood Brain Barrier

Tremors And MS

Uric Acid

Urinary Problems

Vascular Function And MS

Vision and MS

Did you find this information useful? Would you like to comment on this page? Let us know what you think! We welcome all comments and feedback on any aspect of our website - please click here to contact us.